Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 138

1.

A controlled trial of recombinant human erythropoietin and nandrolone decanoate in the treatment of anemia in patients on chronic hemodialysis.

Berns JS, Rudnick MR, Cohen RM.

Clin Nephrol. 1992 May;37(5):264-7.

PMID:
1606777
[PubMed - indexed for MEDLINE]
2.

A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients.

Gaughan WJ, Liss KA, Dunn SR, Mangold AM, Buhsmer JP, Michael B, Burke JF.

Am J Kidney Dis. 1997 Oct;30(4):495-500.

PMID:
9328363
[PubMed - indexed for MEDLINE]
3.

Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease.

Ballal SH, Domoto DT, Polack DC, Marciulonis P, Martin KJ.

Am J Kidney Dis. 1991 Jan;17(1):29-33.

PMID:
1986567
[PubMed - indexed for MEDLINE]
4.

Randomized prospective comparison between erythropoietin and androgens in CAPD patients.

Navarro JF, Mora C, Macía M, García J.

Kidney Int. 2002 Apr;61(4):1537-44.

PMID:
11918762
[PubMed - indexed for MEDLINE]
Free Article
5.

The effects of nandrolone decanoate on nutritional parameters in hemodialysis patients.

Barton Pai A, Chretien C, Lau AH.

Clin Nephrol. 2002 Jul;58(1):38-46.

PMID:
12141405
[PubMed - indexed for MEDLINE]
6.

Use of nandrolone decanoate as an adjuvant for erythropoietin dose reduction in treating anemia in patients on hemodialysis.

Sheashaa H, Abdel-Razek W, El-Husseini A, Selim A, Hassan N, Abbas T, El-Askalani H, Sobh M.

Nephron Clin Pract. 2005;99(4):c102-6. Epub 2005 Feb 8.

PMID:
15703460
[PubMed - indexed for MEDLINE]
7.

Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients.

Carlini R, Obialo CI, Rothstein M.

Am J Hypertens. 1993 Feb;6(2):103-7.

PMID:
8471228
[PubMed - indexed for MEDLINE]
8.
9.

Nandrolone decanoate is a good alternative for the treatment of anemia in elderly male patients on hemodialysis.

Gascón A, Belvis JJ, Berisa F, Iglesias E, Estopiñán V, Teruel JL.

Geriatr Nephrol Urol. 1999;9(2):67-72.

PMID:
10518249
[PubMed - indexed for MEDLINE]
10.

Clinical efficacy of recombinant human erythropoietin in the treatment of anemia in hemodialysis patients: influence of dosing regimen, iron status, and serum aluminum.

Tsai JC, Lai YH, Tsai ZY, Chien LJ, Tsai JH.

Gaoxiong Yi Xue Ke Xue Za Zhi. 1991 Mar;7(3):126-35.

PMID:
1865507
[PubMed - indexed for MEDLINE]
11.

The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.

Kadiroglu AK, Yilmaz ME, Sit D, Kara IH, Isikoglu B.

Ren Fail. 2005;27(4):367-72.

PMID:
16060121
[PubMed - indexed for MEDLINE]
12.

Androgen therapy for anaemia of chronic renal failure. Indications in the erythropoietin era.

Teruel JL, Aguilera A, Marcen R, Navarro Antolin J, Garcia Otero G, Ortuño J.

Scand J Urol Nephrol. 1996 Oct;30(5):403-8.

PMID:
8936631
[PubMed - indexed for MEDLINE]
13.

Androgen versus erythropoietin for the treatment of anemia in hemodialyzed patients: a prospective study.

Teruel JL, Marcen R, Navarro-Antolin J, Aguilera A, Fernandez-Juarez G, Ortuño J.

J Am Soc Nephrol. 1996 Jan;7(1):140-4.

PMID:
8808121
[PubMed - indexed for MEDLINE]
Free Article
14.

Early prediction of response to recombinant human erythropoietin in patients with the anemia of renal failure by serum transferrin receptor and fibrinogen.

Beguin Y, Loo M, R'Zik S, Sautois B, Lejeune F, Rorive G, Fillet G.

Blood. 1993 Oct 1;82(7):2010-6.

PMID:
8400253
[PubMed - indexed for MEDLINE]
Free Article
15.

[Treatment of anemia in patients with chronic renal insufficiency undergoing hemodialysis with recombinant human erythropoietin: 12 months' experience].

de Sousa FT, Prata MM, Barbas JV, dos Santos JP.

Acta Med Port. 1990 Nov-Dec;3(6):347-52. Portuguese.

PMID:
2089856
[PubMed - indexed for MEDLINE]
Free Article
16.

Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial.

Johansen KL, Mulligan K, Schambelan M.

JAMA. 1999 Apr 14;281(14):1275-81.

PMID:
10208142
[PubMed - indexed for MEDLINE]
17.

Nandrolone decanoate reduces serum lipoprotein(a) concentrations in hemodialysis patients.

Teruel JL, Lasuncion MA, Rivera M, Aguilera A, Ortega H, Tato A, Marcen R, Ortuño J.

Am J Kidney Dis. 1997 Apr;29(4):569-75.

PMID:
9100047
[PubMed - indexed for MEDLINE]
18.

The role of nandrolone decanoate in patients with end stage renal disease in the erythropoietin era.

Johansen KL.

Int J Artif Organs. 2001 Apr;24(4):183-5. No abstract available.

PMID:
11394696
[PubMed - indexed for MEDLINE]
19.

Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients.

DeVita MV, Frumkin D, Mittal S, Kamran A, Fishbane S, Michelis MF.

Clin Nephrol. 2003 Nov;60(5):335-40.

PMID:
14640239
[PubMed - indexed for MEDLINE]
20.

Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients.

Movilli E, Cancarini GC, Zani R, Camerini C, Sandrini M, Maiorca R.

Nephrol Dial Transplant. 2001 Jan;16(1):111-4.

PMID:
11209002
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk